Denemek ALTIN - Özgür
Eliminating Silent Killer Through Swift Actions
BioSpectrum Asia
|BioSpectrum Asia July 2024
Hepatitis continues to wreak havoc globally, with the latest World Health Organization WHO) report sounding alarms on viral hepatitis infections claiming 3,500 lives each day. The WHO estimates from 2022 reveal that 254 million people live with hepatitis B and 50 million with hepatitis C. The Asia Pacific APAC) region is at the epicentre of this crisis, hosting the top 7 highburden countries. Let's discuss the progress of the region towards achieving the 2030 targets for hepatitis elimination and identify what actions are needed to achieve these goals.
According to the WHO 2024 Global Hepatitis Report, viral hepatitis is on the rise and remains the second leading infectious cause of death globally, claiming 1.3 million lives annually, equivalent to tuberculosis. Ten countries account for nearly two-thirds of the global burden of viral hepatitis B and C: China, India, Indonesia, Nigeria, Pakistan, Ethiopia, Bangladesh, Vietnam, The Philippines and the Russian Federation.
The APAC region is disproportionately affected, with 70 per cent of viral hepatitis deaths occurring here. Failure to act swiftly could lead to substantial economic losses, with projected costs of $558 billion for hepatitis B and $62 billion for hepatitis C due to illness and premature mortality, according to the Coalition for Global Hepatitis Elimination report.
WHO has set a goal to eliminate viral hepatitis by 2030, aiming for a 90 per cent reduction in incidence and a 65 per cent reduction in mortality from hepatitis B and C.
Progress so far
Most of the countries in the region have a national hepatitis elimination programme but progress remains somewhat unsatisfactory.
“Viral hepatitis has a devastating impact on South-East Asia and the Western Pacific regions, where an estimated 158 million people live with chronic hepatitis B and 16 million with chronic hepatitis C. Access to treatment for hepatitis B and C remains a challenge in many Asian countries due to cost and healthcare infrastructure limitations. Furthermore, vertical transmission (from mother to child) of hepatitis B is a major concern in the region. Such a heavy prevalence has a profound disruptive effect on society in the region. On top of causing a tragic loss of life, viral hepatitis poses a huge societal and financial burden and drives inequality,” said
Benedetta Nirta, Deputy Director and Fundraising Manager at The Hepatitis Fund, Geneva.
Bu hikaye BioSpectrum Asia dergisinin BioSpectrum Asia July 2024 baskısından alınmıştır.
Binlerce özenle seçilmiş premium hikayeye ve 9.000'den fazla dergi ve gazeteye erişmek için Magzter GOLD'a abone olun.
Zaten abone misiniz? Oturum aç
BioSpectrum Asia'den DAHA FAZLA HİKAYE
BioSpectrum Asia
Malaysia, Thailand implement medical device reliance programme after successful pilot
The Medical Device Authority (MDA) of Malaysia and the Thai Food and Drug Administration (Thai FDA) signed a Confidentiality Agreement to deepen regulatory cooperation and officially launched a 3-month pilot of the Medical Device Regulatory Reliance Programme as part of the agreement.
1 min
BioSpectrum Asia June 2026
BioSpectrum Asia
Strand Life Sciences launches South Asia's first Olink Explore HT Proteomics Service
India-based Strand Life Sciences, a subsidiary of Reliance Industries Limited, has announced the launch of its advanced proteomics capabilities powered by Olink Explore HT, marking a key milestone in expanding largescale multi-omics research in South Asia.
1 min
BioSpectrum Asia June 2026
BioSpectrum Asia
UK transforms mental healthcare with new strategy
Frontline workers, clinicians and mental health experts are being invited to share their views on how to transform mental healthcare for children and adults in England, as the government launches a call for evidence to shape its once-in-a-generation crossgovernment mental health strategy.
1 min
BioSpectrum Asia June 2026
BioSpectrum Asia
Australia Budget 2026-27: Investing in Care, Health and Innovation.
The Australian Federal Budget 2026-27, presented by the Albanese Government, places strong emphasis on healthcare, aged care, T disability services, research, innovation and social equality.
4 mins
BioSpectrum Asia June 2026
BioSpectrum Asia
Gavi proposes new incentives for advancing vaccine manufacturing in Africa
With Gavi's African Vaccine Manufacturing Accelerator (AVMA) expected to make its first cash disbursement to an African vaccine manufacturer in the second half of 2026, Gavi, the Vaccine Alliance has proposed further measures totaling $189 million of additional investment to further aid development of Africa's vaccine manufacturing sector.
1 min
BioSpectrum Asia June 2026
BioSpectrum Asia
New WHO online course strengthens good practices in clinical trials
High-quality clinical trials are essential for generating reliable evidence to inform health policy, clinical practice and public trust in science.
1 min
BioSpectrum Asia June 2026
BioSpectrum Asia
World Bank approves $225 M to improve healthcare in Côte d'Ivoire
The World Bank has approved $225 million in financing to help Côte d'Ivoire improve the delivery of quality health, nutrition, and early childhood development services for millions of people, particularly for women, children, and vulnerable households.
1 min
BioSpectrum Asia June 2026
BioSpectrum Asia
Nona Biosciences appoints Dr Josh Xiao as CSO
Nona Biosciences, a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, has announced the appointment of Dr Josh Xiao as Chief Scientific Officer (CSO). Dr Xiao will be based in both the US and China and report directly to Dr Di Hong, Chief Executive Officer of Nona Biosciences.
1 min
BioSpectrum Asia June 2026
BioSpectrum Asia
Korea lays focus on stabilising medical product supply
The Ministry of Health and Welfare (MoHW), South Korea government, recently held its 7th meeting with healthcare and pharmaceutical associations, bringing together the Ministry of Trade, Industry and Resources (MOTIR), and the Ministry of Food and Drug Safety (MFDS).
1 min
BioSpectrum Asia June 2026
BioSpectrum Asia
Formosa Pharma partners with SERI to advance novel ophthalmic formulations for corneal diseases
Taiwan-based Formosa Pharmaceuticals, Inc. and the Singapore Eye Research Institute (SERI) have announced a strategic research collaboration to develop next-generation ophthalmic formulations.
1 min
BioSpectrum Asia June 2026
Listen
Translate
Change font size
